New research links GLP-1 drugs like Ozempic and Wegovy to lower risk of depression, anxiety, and substance use disorders. Here’s what you need to know.
GLP-1 Drugs: More Than Weight Loss
GLP-1 drugs, such as Ozempic, Wegovy, and Rybelsus, have become household names for managing weight and type 2 diabetes. But recent research suggests these medications may offer an unexpected bonus: protecting mental health.
A study published in Lancet Psychiatry found that semaglutide, the active ingredient in these drugs, is linked to a lower risk of worsening anxiety, depression, and even substance use disorders.
The Study Behind the Headlines
Researchers analysed health data from 95,490 people in Sweden, using the country’s comprehensive national registry. Among participants, 81% had anxiety, 55% had depression, and 36% had both.
The study compared periods when participants were taking GLP-1 medications to periods when they weren’t. The results? Semaglutide was associated with:
42% lower risk of worsening overall mental health
38% lower risk of worsening anxiety
44% lower risk of worsening depression
47% lower risk of worsening substance use disorders
Liraglutide, sold as Victoza in Canada, also showed benefits, though more modest, reducing the risk of mental illness by 18%.
Dr. Hertzel Gerstein, a professor at McMaster University and Hamilton Health Sciences, called the findings “significant” but cautioned that these results are observational.
Observational, Not Definitive
While the study is large and thorough, it has limitations. Researchers stressed that correlation does not equal causation. The findings suggest a connection, but they don’t prove that GLP-1 drugs directly improve mental health.
Dr. Gerstein explained, “To confirm causality, we’d need a randomized trial where some participants take semaglutide and others don’t, then track changes in depression or anxiety over time.”
Additionally, access may be a challenge in countries without universal healthcare, as GLP-1 medications can be expensive until generics become available.
Promising but Not Risk-Free
GLP-1 drugs continue to show benefits beyond mental health, from potential heart and kidney protection to helping with osteoarthritis. However, risks exist.
A 2023 University of British Columbia study linked GLP-1 drugs to stomach paralysis, pancreatitis, and bowel obstruction.
A 2024 Harvard study noted increased risk of sudden, irreversible vision loss.
The European Medicines Agency warned that Wegovy may rarely cause a serious eye condition called non-arteritic anterior ischemic optic neuropathy (NAION).
Common side effects include nausea, bloating, constipation, and stomach pain, while rare cases report dizziness, confusion, or fainting.
What This Means for Canadians
For Canadians struggling with mental health challenges, GLP-1 drugs may hold unexpected promise. But experts emphasize caution and consultation with a healthcare provider. While semaglutide could become part of future mental health strategies, the next step is rigorous clinical trials to confirm its effects.
The message is clear: GLP-1 drugs may not just change bodies—they might change minds too, but science still needs to catch up before making broad claims.
